Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncology. 2012;82(1):56-8. doi: 10.1159/000334999. Epub 2012 Feb 4.

Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.

Author information

  • 1School of Medicine and Public Health, The University of Newcastle, Callaghan, N.S.W., Australia.

Abstract

OBJECTIVE:

To determine if 6 months of neo-adjuvant androgen deprivation is associated with the long-term risk of cardiac mortality.

METHODS:

In the TROG 96.01 trial, 802 men with locally advanced prostate cancer were randomized to radiotherapy either alone or with 3 or 6 months of neo-adjuvant androgen deprivation therapy (NADT). Competing risk methodology was used to derive the cumulative incidence of fatal cardiac events.

RESULTS:

At 10 years, the cumulative incidence of fatal cardiac events for the radiation therapy alone arm was 7.54% compared to a nonstatistically significant decreased incidence of 6.44% in the 6-month NADT arm (p = 0.65). Men aged over 65 years were not at an increased risk. Additional androgen deprivation therapy given as secondary treatment at tumor progression did not confer an increased risk.

CONCLUSION:

These data suggest that fatal cardiac events are not more common in men receiving up to 6 months of NADT.

Copyright © 2012 S. Karger AG, Basel.

PMID:
22310055
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk